









Markets
/
Stocks
/
nasdaq-cgen
/

Compugen Ltd

CGEN

1.670USD

+0.080+5.03%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

156.20MMarket Cap

LossP/E TTM



Compugen Ltd

1.670

+0.080+5.03%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Compugen Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Compugen Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 146 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 6.25.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Compugen Ltd's Score

Industry at a Glance

Industry Ranking

146 / 392

Overall Ranking

291 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Compugen Ltd Highlights

StrengthsRisks

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 271.52% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 27.86M.

Fairly Valued

The company’s latest PE is -5.58, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 1.41M shares of this stock.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

6.250

Target Price

+293.08%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Compugen Ltd is 6.25, ranking 277 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.89M, representing a year-over-year decrease of 88.96%, while its net profit experienced a year-over-year decrease of 646.94%.

Score

Industry at a Glance

Previous score

6.25

Change



Financials

8.68

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.54

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.04

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Compugen Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Compugen Ltd is 6.50, ranking 264 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.58, which is -1733.52% below the recent high of 91.17 and -259.39% above the recent low of -20.06.

Score

Industry at a Glance

Previous score

6.50

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 146/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Compugen Ltd is 9.20, ranking 9 out of 392 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 13.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

6.250

Target Price

+293.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Compugen Ltd

CGEN

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Compugen Ltd is 6.67, ranking 196 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.17 and the support level at 1.37, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

0.18

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.122

Neutral

RSI(14)

41.308

Neutral

STOCH(KDJ)(9,3,3)

11.123

Oversold

ATR(14)

0.108

Low Volatility

CCI(14)

-121.911

Sell

Williams %R

88.737

Oversold

TRIX(12,20)

0.274

Sell

StochRSI(14)

47.927

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

1.726

Sell

MA10

1.840

Sell

MA20

1.960

Sell

MA50

1.715

Sell

MA100

1.688

Sell

MA200

1.601

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Compugen Ltd is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 17.35%, representing a quarter-over-quarter decrease of 5.37%. The largest institutional shareholder is James Simons, holding a total of 1.41M shares, representing 1.50% of shares outstanding, with 3.57% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

SilverArc Capital Management, LLC

3.31M

+9.14%

Bristol Myers Squibb

1.84M

-61.32%

Renaissance Technologies LLC

Star Investors

1.41M

+5.90%

Nomura Investment Management Business Trust

1.02M

Morgan Stanley Smith Barney LLC

870.81K

+3.30%

Taylor Frigon Capital Management LLC

964.71K

-3.01%

Northern Trust Global Investments Limited

658.91K

-25.94%

Two Sigma Investments, LP

455.66K

+33.07%

State Street Investment Management (US)

379.10K

+7.95%

UBS Financial Services, Inc.

296.60K

+2.13%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Compugen Ltd. The Biotechnology & Medical Research industry's average is 3.38. The company's beta value is 2.92. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.